Speaker illustration

Professor Ingo Hilgendorf

University of Freiburg, Freiburg (Germany)

Member of:

European Society of Cardiology

The physician`s perspective: what prevents us from keeping LDL-C lower for longer? Who are the patients that need more help?

Event: ESC Congress 2022

Topic: Lipid-Lowering Agents

Session: Lower for longer: reframing the clinical goal for LDL-C. The lower the better is no longer enough


NLRP3 mediates atheromatous plaque macrophage proliferation

Event: ESC Congress 2022

Topic: Leukocytes, Inflammation, Immunity

Session: Atherosclerosis and inflammation


Incorporating Lp(a) into risk classification for patients with ASCVD.

Event: ESC Congress 2022

Topic: Cardiovascular Risk Assessment

Session: Uncovering the hidden risk: why lipoprotein(a) testing is crucial


Lipid im- and exporters differentially determine macrophage turnover in the plaque

Event: ESC Congress 2017

Topic: Lipids

Session: Lipids, cardiac pathology


SYK inhibitor fostamtinib protects from early but not established atherosclerosis when local macrophage proliferation dominates lesion turnover

Event: ESC Congress 2016

Topic: Atherosclerosis

Session: Best Posters in atherosclerosis


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb